AAPG News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AA

Mkt Cap

$1.43B

Volume

14.76K

Loading chart

AA

AAPGAscentage Pharma Group International American Depository Shares

AAPG

Pay with—

Available Balance0.00

AA

Mkt Cap

$1.37B

Volume

14.76K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial OfficerAscentage Pharma announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and US commercialization efforts. Both executives bring extensive experience in oncology and specialty therapeutics, with the company advancing multiple Phase III registrational studies for its pipeline of cancer therapies.GlobeNewswire Inc. · Aug 2, 2026

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.GlobeNewswire Inc. · Jul 26, 2026

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 CongressAscentage Pharma announced seventeen clinical updates from its core assets at the 31st European Hematology Association Congress, including eight poster presentations. Key data showed olverembatinib demonstrated deep and durable responses in chronic myeloid leukemia (CML) patients resistant to first-line therapy and robust clinical response in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax showed promising efficacy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid neoplasms, with a chemotherapy-free combination regimen yielding encouraging results in pediatric patients with relapsed/refractory Ph+ ALL.GlobeNewswire Inc. · Jun 14, 2026

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026Ascentage Pharma presented clinical data on alrizomadlin (APG-115), an MDM2-p53 inhibitor, for treating pediatric solid tumors at ASCO 2026. The drug showed preliminary antitumor activity with manageable safety profiles as monotherapy and in combination with lisaftoclax, achieving a 23.5% objective response rate in the combination arm. Alrizomadlin was included in China's SPARK Plan for pediatric oncology development.GlobeNewswire Inc. · May 31, 2026

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO Annual Meeting, marking its ninth consecutive appearance.GlobeNewswire Inc. · May 31, 2026

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating patients who failed first-line TKI therapy.GlobeNewswire Inc. · May 31, 2026

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association CongressAscentage Pharma Group International announced that 17 clinical advances of its core assets, including 8 poster presentations, will be featured at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm from June 11-14, 2026. The presentations showcase data from ongoing clinical studies of Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor, across various hematologic malignancies and leukemia indications.GlobeNewswire Inc. · May 13, 2026

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026Ascentage Pharma announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations and three poster presentations. The presentations will showcase data on Olverembatinib (HQP1351), Lisaftoclax (APG-2575), and Alrizomadlin (APG-115) across various cancer indications. This marks the company's ninth consecutive year presenting at ASCO.GlobeNewswire Inc. · Apr 22, 2026

Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business UpdatesAscentage Pharma reported 2025 product sales and commercial rights revenues increased 90% year-over-year to US$82.1 million, driven by Olverembatinib sales growth of 81% to US$62.2 million and new Lisaftoclax sales of US$10.1 million following its July 2025 launch in China. The company is advancing nine registrational Phase III clinical trials globally, with four cleared by FDA and EMA. Despite strong commercial progress, the company reported a net loss of US$177.7 million for 2025.GlobeNewswire Inc. · Mar 25, 2026

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026Ascentage Pharma announced it will release its full year 2025 unaudited financial results and business updates on March 25, 2026, with separate English and Mandarin language investor webcasts. The company, a global biopharmaceutical firm focused on cancer therapies, has two approved products (Olverembatinib and Lisaftoclax) and is conducting multiple Phase III clinical trials.GlobeNewswire Inc. · Mar 11, 2026

to start trading

AA

AAPGAscentage Pharma Group International American Depository Shares

AAPG

Pay with—

Available Balance0.00

Your PositionYou don't own any AAPG yet.

Related Tickers

Earnings